(Q45874257)

17 December 2017

title

Treatment of pulmonary hypertension: bench to bedside (English)

1 reference

17 December 2017

2

Mitja Lainscak

1 reference

17 December 2017

4

Irene M Lang

1 reference

17 December 2017

author name string

Jochen Springer

series ordinal

1

1 reference

17 December 2017

Barbara Salobir

series ordinal

3

1 reference

17 December 2017

publication date

1 October 2011

1 reference

17 December 2017

published in

Respiratory Medicine

1 reference

17 December 2017

volume

105 Suppl 1

1 reference

17 December 2017

page(s)

S7-11

1 reference

17 December 2017

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Vasodilator therapy for primary pulmonary hypertension. Limitations and hazards

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Pulmonary and systemic vasodilator effects of the newly discovered prostaglandin, PGI2

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Advance in understanding the biosynthesis of prostacyclin and thromboxane A2 in the endoplasmic reticulum membrane via the cyclooxygenase pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Defining the role of endothelins in renal pathophysiology on the basis of selective and unselective endothelin receptor antagonist studies

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Endothelin receptor is coupled to phospholipase C via a pertussis toxin-insensitive guanine nucleotide-binding regulatory protein in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Endothelin receptor antagonists in pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Tadalafil therapy for pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

An epidemiological study of pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Beta-estradiol attenuates hypoxic pulmonary hypertension by stabilizing the expression of p27kip1 in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

p27(Kip1) is important in modulating pulmonary artery smooth muscle cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

The serotonin transporter, gender, and 17β oestradiol in the development of pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Angiotensin-converting enzyme 2 protects from severe acute lung failure

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Targeting the vasoprotective axis of the renin-angiotensin system: a novel strategic approach to pulmonary hypertensive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Role of the RhoA/Rho-kinase pathway in the regulation of pulmonary vasoconstrictor function

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

KMUP-1 inhibits pulmonary artery proliferation by targeting serotonin receptors/transporter and NO synthase, inactivating RhoA and suppressing AKT/ERK phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Gene microarray analysis of peripheral blood cells in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Primary pulmonary hypertension: Current therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Microvascular regeneration in established pulmonary hypertension by angiogenic gene transfer.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

In vivo gene transfer of prepro-calcitonin gene-related peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Adenoassociated virus-mediated prostacyclin synthase expression prevents pulmonary arterial hypertension in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

A meta-analysis of randomized controlled trials in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970004-X

7 January 2021

10.1016/S0954-6111(11)70004-X

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017